



# Quarterly Report II

# 2011



		Q1-2/2011	Q1-2/2010	Change
Sales	Million EUR	55.8	52.9	5%
Return on revenue before tax	%	20%	18%	13%
EBITDA	Million EUR	15.4	13.9	11%
EBIT	Million EUR	11.9	10.0	19%
EBT	Million EUR	11.2	9.4	19%
Net income before other shareholder's interests	Million EUR	7.1	5.9	20%
Profit	Million EUR	6.6	5.1	28%
Earnings per share (basic)	Million EUR	1.26	0.99	27%
Operational cash flow	Million EUR	5.3	5.6	-4%
Depreciation and amortization on non-current assets	Million EUR	3.5	3.9	-9%
Staff as of June 30	Persons	562	534	5%



## Theragenics

Eckert & Ziegler withdraws offer to acquire Theragenics.

## Foundation Stone

Berlin's Governing Mayor, Klaus Wowereit, lays the Foundation Stone for the new Corporate Head Office of Eckert & Ziegler AG. (1)

## Dividend

A dividend in the amount of EUR 0.60 is decided at the Annual General Meeting on 19 May 2011. (2)

## Man of Action

On behalf of the whole Eckert & Ziegler team, Andreas Eckert accepts the Mittelstands-Award „Man of Action 2011“. (3)

## Renate Künast

The chairwoman of the Bundestag (Lower house of the German parliament) faction Bündnis 90/Die Grünen (The German Green party), Renate Künast, visits Eckert & Ziegler AG within the framework of an information meeting at the science campus Berlin-Buch. (4)

## Change of Name

IBt Bebig changes its name to Eckert & Ziegler BEBIG.

# Business development of the Eckert & Ziegler Group

## Excellent 1<sup>st</sup> half-year 2011

The second quarter 2011 developed extraordinarily successful for the Eckert & Ziegler Group. The revenue was exceeded slightly compared with the second quarter of 2010 and the profit after taxes and minorities rose by 13%. Together with the even stronger first quarter of 2011 the best half-year results in the history of the company are produced. The revenue increased by 5% to EUR 55.8 million compared with the first six months of the previous year. The EBIT rose by 19% to EUR 11.9 million and the results after taxes and minorities increased by 28% to EUR 6.6 million. Earnings per share for the first half-year in 2011 are EUR 1.26 per share.

The Isotope Products segment accounts for the greatest share of the total results. The revenue rose by 9% here. All product categories recorded growth. In the ratio to the revenue the costs only increased less than proportionate owing to economies of scale. Thus, EBIT could be increased by 19%.

The Radiopharma segment recorded the strongest growth. Increases were also achieved here in all product lines. In total the segment increased the half-year revenue by 25% to EUR 12.4 million. Particularly pleasing in this context is the group-wide maximum gross profits of 60% so that here, even more than in the segment Isotope Products, a large part of the growth in revenue is reflected in the profits.

The Radiation Therapy segment (previously: Therapy) could not as expected achieve the record revenue of the previous year. Profits were realised from the plant sale to Russia in the comparable period of the previous year. Comparable are therefore only the figures within the year 2011. The revenue remained almost constant compared with the previous quarter. It was nevertheless possible to increase the profit as the sales and management costs fell. Detailed statements relating to the Radiation Therapy segment can be taken from the semi-annual report of Eckert & Ziegler BEBIG S.A. (previously: IBt S.A.) which is published at the same time ([www.bebig.eu](http://www.bebig.eu)). In the Profit and Loss segment there are smaller shifts and valuation differences between the Eckert & Ziegler Group and the BEBIG financial statements which are presented in the table below.

The revenue with external customers is constant compared with the previous year in the Environmental Services segment. As however orders are also placed within the Group and moreover costs were saved there are no losses suffered any more as opposed to the previous year. Unfortunately this does not apply to the Miscellaneous segment which contains the allocations and costs of the holding. The segment increased by EUR 0.2 million. Responsible for this are the personnel costs for additional employees. In addition, the interest income from other segment fell as a result of redemptions which were carried out in the meantime.

	Radiation Therapy segment of Eckert & Ziegler AG	Semi-annual report of the listed Eckert & Ziegler BEBIG S.A.	Deviation	Thereof depreciation customer base
	TEUR	TEUR	TEUR	TEUR
<b>Revenues</b>	<b>13,085</b>	<b>13.085</b>	-	-
Costs	-11,967	-11.783	-184	-184
<b>EBT</b>	<b>1,118</b>	<b>1.302</b>	<b>-184</b>	<b>-184</b>
Income tax expense	-613	-613	-	-
<b>Net income</b>	<b>505</b>	<b>689</b>	<b>-184</b>	<b>-184</b>
Profit/loss attributable to minority interests	-134			
<b>Dividend to shareholders to Eckert &amp; Ziegler AG</b>	<b>371</b>			

## Liquidity

The cash flow statement features a gross cash flow (cash inflow from operational activity before the change in the short-term assets and liabilities) of EUR 11.4 million for the first six months of 2011. Thus the gross cash flow is 20% above the value of the previous year of EUR 9.5 million. The increase comes above all from the period results which have increased by 26%.

In particular the increase of receivables and inventories by EUR 4.5 million led to the fact that the cash inflow from operational activity fell by EUR 0.2 million to EUR 5.3 million compared with the previous year despite the higher profit.

The investments increased sharply from EUR 2.4 million to EUR 5.6 million compared with the previous year. The introduction of a standard ERP-System group-wide is mainly responsible for the increase.


The dividend payment increased by 36% to EUR 3.2 million. External capital was redeemed approximately to the same extent. On balance EUR 2.9 million were redeemed. In the first six months of the previous year on the other hand new external capital of balanced EUR 6.2 million were borrowed and a payment was made from the IBt take-over of EUR 22.5 million.

Together with a devaluation of the liquid funds of EUR 0.5 million, due to exchange rates, a fall in the liquidity is produced by EUR 6.8 million to 22.4 million during the first half-year of 2011.

## Balance sheet

Compared with December 31, 2010 the balance sheet only changed marginally in the first half-year of 2011. The balance sheet total fell by EUR 4 million. The change can be found on the assets side in the short-term assets. The liquid funds fell by EUR 7 million there, whereas the receivables and inventories increased by EUR 3 million. The liabilities fell by EUR 7 million owing to loan redemptions and reduction of provisions. The equity increased by EUR 3 million as the half-year results substantially exceeded the dividend payment of May. The equity ratio thus increased from 51% to 54%.

## External sales (in Mio. EUR)





## Research and Development

A further accessory was developed ready for launch on the market for the cancer radiation device MultiSource® in the Radiopharma segment. Fletcher applicators, intra-uterine pens and a set of transfer tubes were fitted with a new colour coding. In interaction with the new MultiSource® this increases the safety for the patient and the operating comfort for the clinical user. Together with the production a process for casting biocompatible plastics was qualified with which new, complex applicator types can be developed and produced independently in future.

A prototype of the so-called MicroCell was developed for the synthesis device system Modular-Lab in the Radiopharma segment. This module for the fully automatic processing of radioactive liquids in nuclear medicine is substantially smaller, lighter and more reasonably priced than the "hot cell" which is necessary as a standard for the handling of radioactive substances. This enables hospitals to save costs and time with the installation and is also a practical solution for practices in nuclear medicine.

In the Isotope Products segment, which produces sources for measurement technology, the subsidiary Eckert & Ziegler Isotope Products developed a new product line ready for launch on the market: Cf-252 Neutron sources for industrial mineral analysis equipment. This new line of sources is used for the accurate measurement of minerals in coal or cement and for moisture content in bulk storage silos. The Californian subsidiary is already the market leader for low level radioactive Cf-252 sources, which are used in portable moisture measurement devices supplied to the construction industry.


## Employees

As of 30 June 2011 the Eckert & Ziegler Group employed 386 employees in Germany and 562 employees worldwide. Compared with the end of 2010 the number of employees increased by 16 (31 December 2010: 546). The increases can be found especially in the Isotope Products (+ 9; essentially in Braunschweig) and Radiation Therapy segments (+ 4; mainly acquisition sonoTECH GmbH).

## Outlook

The revenue target is EUR 110 to 120 million for the fiscal year 2011. The Board of Directors reinforces its profit forecast of EUR 2.00 per share (results after taxes and minorities > EUR 10 million). The acquired radiopharmaceutical device business in the USA does not lead to a significant change in the revenue and income targets.

### Profit after taxes (in Mio. EUR)



Group Statement of Income	Quarterly Report II/2011 04-06/2011	Quarterly Report II/2010 04-06/2010	6-monthly Report 01-06/2011	6-monthly Report 01-06/2010
	TEUR	TEUR	TEUR	TEUR
<b>Revenues</b>	<b>27,530</b>	<b>27,182</b>	<b>55,774</b>	<b>52,884</b>
Cost of sales	- 11,941	- 12,962	- 23,823	- 24,574
<b>Gross profit on sales</b>	<b>15,589</b>	<b>14,220</b>	<b>31,951</b>	<b>28,310</b>
Selling expenses	- 4,843	- 5,185	- 9,439	- 9,442
General and administrative expenses	- 4,989	- 4,493	- 9,717	- 9,253
Research and non-capitalized development expenses	- 712	- 455	- 1,179	- 1,034
Other operating income	586	336	815	1,045
Other operating expenses	- 43	- 31	- 122	- 248
<b>Profit from operations</b>	<b>5,588</b>	<b>4,392</b>	<b>12,309</b>	<b>9,378</b>
Earnings from shareholdings accounted for using the equity method	-	-	-	-
Other financial results	- 68	436	- 383	638
<b>Earnings before interest and taxes (EBIT)</b>	<b>5,520</b>	<b>4,828</b>	<b>11,926</b>	<b>10,016</b>
Interest received	20	67	34	123
Interest paid	- 363	- 285	- 750	- 718
<b>Profit before tax</b>	<b>5,177</b>	<b>4,610</b>	<b>11,210</b>	<b>9,421</b>
Income tax expense	- 1,950	- 1,567	- 4,156	- 3,562
<b>Net income</b>	<b>3,227</b>	<b>3,043</b>	<b>7,054</b>	<b>5,859</b>
Profit/loss attributable to minority interests	- 280	- 432	- 484	- 732
<b>Dividend to shareholders of Eckert &amp; Ziegler AG</b>	<b>2,947</b>	<b>2,611</b>	<b>6,570</b>	<b>5,127</b>
<b>Earnings per share</b>				
Basic	0,56	0,51	1,26	0,99
Diluted	0,56	0,51	1,26	0,98
Average number of shares in circulation (basic)	5,221	5,141	5,221	5,194
Average number of shares in circulation (diluted)	5,221	5,163	5,221	5,216

Group Statement of Comprehensive Income	Quarterly Report Q II/2011 04-06/2011	Quarterly Report Q II/2010 04-06/2010	6-monthly Report 01-06/2011	6-monthly Report 01-06/2010
	TEUR	TEUR	TEUR	TEUR
<b>Profit for the period</b>	<b>3,227</b>	<b>3,043</b>	<b>7,054</b>	<b>5,859</b>
Of which attributable to other shareholders	280	432	484	732
Of which attributable to shareholders of Eckert & Ziegler AG	2,947	2,611	6,570	5,127
Adjustment to fair value of available for-sale financial assets	0	1	0	3
Amount reposted to income statement	0	0	0	0
Profit tax	0	0	0	-1
<b>Adjustment of amount recorded in shareholders' equity (Financial assets available-for-sale)</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>2</b>
Adjustment of balancing item from the currency translation of foreign subsidiaries	-620	1,663	-1,381	2,684
Amount reposted to income statement	0	0	0	0
<b>Adjustment of amount recorded in shareholders' equity (Currency translation)</b>	<b>-620</b>	<b>1,663</b>	<b>-1,381</b>	<b>2,684</b>
<b>Total of value adjustments recorded in shareholders' equity</b>	<b>-620</b>	<b>1,664</b>	<b>-1,381</b>	<b>2,686</b>
Of which attributable to other shareholders	5	-10	18	20
Of which attributable to shareholders of Eckert & Ziegler AG	-625	1,674	-1,399	2,666
<b>Total from net income and value adjustments recorded in shareholders' equity</b>	<b>2,607</b>	<b>4,707</b>	<b>5,673</b>	<b>8,545</b>
Of which attributable to other shareholders	285	422	502	752
Of which attributable to shareholders of Eckert & Ziegler AG	2,322	4,285	5,171	7,793



Group Statement of Cash Flows	6-monthly Report 01-06/2011	6-monthly Report 01-06/2010
	TEUR	TEUR
<b>Cash flows from operating activities:</b>		
Profit for the period	7,052	5,589
Adjustments for:		
Depreciation	3,513	3,871
Proceeds from grants less release of deferred income from grants	- 167	- 133
Long-term provisions, other non-current liabilities	- 660	384
Gains (-)/losses on the disposal of non-current assets	7	- 4
Miscellaneous	1,608	- 245
Changes in current assets and liabilities:		
Receivables	- 3,478	- 1,713
Inventories	- 1,041	958
Accruals, other current assets	93	- 57
Change in the current liabilities and provisions	- 1,585	- 3,066
<b>Cash inflows generated from operating activities</b>	<b>5,342</b>	<b>5,584</b>
<b>Cash flows from investment activities:</b>		
Purchase (-)/sale of non-current assets	- 5,609	- 2,363
<b>Cash outflows from investment activity</b>	<b>- 5,609</b>	<b>- 2,363</b>
<b>Cash flows from financing activities:</b>		
Paid dividends	- 3,173	- 2,335
Distribution of shares of third parties	-	- 59
Change in long-term borrowings	- 2,613	6,191
Change in short-term borrowings	- 305	- 426
Sales of own shares and cash inflow from the exercising of stock options	-	712
Aquisition of shares of consolidated companies	-	- 22,539
<b>Cash outflows from financing activities</b>	<b>- 6,091</b>	<b>- 18,456</b>
Effect of exchange rates on cash and cash equivalents	- 469	722
<b>Increase/reduction in cash and cash equivalents</b>	<b>- 6,827</b>	<b>- 14,513</b>
<b>Cash and cash equivalents at beginning of period</b>	<b>29,216</b>	<b>43,674</b>
<b>Cash and cash equivalents at end of period</b>	<b>22,389</b>	<b>29,161</b>

Group Balance Sheets	June 30, 2011	December 31, 2010
	TEUR	TEUR
<b>ASSETS</b>		
<b>Non-current assets</b>		
Goodwill	29,696	30,410
Other intangible assets	10,654	10,475
Property, plant and equipment	28,757	27,602
Investments valued according to the equity method	108	108
Deferred tax	11,248	12,204
Other non-current assets	928	1,220
<b>Total non-current assets</b>	<b>81,391</b>	<b>82,019</b>
<b>Current assets</b>		
Cash and cash equivalents	22,389	29,216
Securities	224	224
Trade accounts receivable	19,727	17,252
Inventories	13,487	12,678
Other current assets	3,529	3,078
<b>Total current assets</b>	<b>59,356</b>	<b>62,448</b>
<b>Total assets</b>	<b>140,747</b>	<b>144,467</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Capital and reserves</b>		
Subscribed capital	5,293	5,293
Capital reserves	53,874	53,874
Retained earnings	14,752	11,729
Other reserves	- 3,582	- 2,183
Own shares	- 27	- 401
Portion of equity attributable to the shareholders of Eckert & Ziegler AG	70,310	68,312
Minority interests	5,795	5,293
<b>Total shareholders' equity</b>	<b>76,105</b>	<b>73,605</b>
<b>Non-current liabilities</b>		
Long-term borrowings and finance lease obligations	13,582	16,009
Deferred income from grants and other deferred income	526	584
Deferred tax	632	647
Retirement benefit obligations	6,053	5,913
Other provisions	17,305	17,841
Other non-current liabilities	453	1,118
<b>Total non-current liabilities</b>	<b>38,551</b>	<b>42,112</b>
<b>Current liabilities</b>		
Short-term borrowings and finance lease obligations	5,270	5,794
Trade accounts payable	4,074	4,323
Advance payments received	3,187	3,374
Deferred income from grants and other deferred income	381	536
Current tax payable	1,586	1,112
Other current liabilities	11,593	13,611
<b>Total current liabilities</b>	<b>26,091</b>	<b>28,750</b>
<b>Total equity and liabilities</b>	<b>140,747</b>	<b>144,467</b>

	Subscribed capital				Cumulative other equity items						
	Number	Nominal value	Capital reserve	Retained reserves	Unrealized profit securities	Unrealized profit pension commitments	Foreign currency exchange differences	Own shares	Equity attributable to shareholders' equity	Minority shares	Group share holders' equity
	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR
As of January 1, 2010	5,260,283	5,260	52,719	21,955	4	-149	-3,234	-703	75,852	10,223	86,075
Foreign currency translation differences							1,047		1,047	-16	1,031
Unrealized gains/losses on performanceorientated pension commitments at balance sheet date (after tax of EUR -0)						1			1		1
Unrealized gains/losses on securities at balance sheet date (after tax of EUR -1)					3				3		3
Reversal of unrealized gains/losses on securities at previous balance sheet date				-4	149				145		145
Total of expenditures and income directly entered in equity	0	0	0	0	-1	150	1,047	0	1,196	-16	1,180
Net profit for the year				9,413					9,413	1,002	10,415
Total income for the period	0	0	0	9,413	-1	150	1,047	0	10,609	986	11,595
Dividends paid				-2,335					-2,335	-351	-2,686
Purchase or sale of minority interests				-17,304					-17,304	-5,565	-22,869
Sale of own shares for purchase of minority interests			583					189	772		772
Sale of own shares			368					113	481		481
Capital increases	32,700	33	204						237		237
As of December 31, 2010	5,292,983	5,293	53,874	11,729	3	1	-2,187	-401	68,312	5,293	73,605
As of January 1, 2011	5,292,983	5,293	53,874	11,729	3	1	-2,187	-401	68,312	5,293	73,605
Foreign currency translation differences							-1,399		-1,399	18	-1,381
Unrealized gains/losses by performance oriented pensions on balance sheet date (after tax of EUR 0)						1			1		1
Unrealized gains/losses on securities at balance sheet date (after tax of EUR 3 thousand)					3				3		3
Reversal of unrealized gains/losses at previous balance sheet date					-3	-1			-4		-4
Total of expenditures and income directly entered in equity	0	0	0	0	0	0	-1,399	0	-1,399	18	-1,381
Net profit for the year				6,570					6,570	484	7,054
Total income for the period	0	0	0	6,570	0	0	-1,399	0	5,171	502	5,673
Dividends paid				-3,173					-3,173		-3,173
Purchase or sale of minority interests				-374				374	0	0	0
As of June 30, 2011	5,292,983	5,293	53,874	14,752	3	1	-3,586	-27	70,310	5,795	76,105

	Isotope Products		Radiation Therapy		Radiopharma		Environmental Services		Others		Elimination		Total	
	01-06 2011	01-06 2010	01-06 2011	01-06 2010	01-06 2011	01-06 2010	01-06 2011	01-06 2010	01-06 2011	01-06 2010	01-06 2011	01-06 2010	01-06 2011	01-06 2010
	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR
Sales to external customers	27,748	25,483	12,986	14,769	12,441	9,980	2,599	2,652	0	0	0	0	55,774	52,884
Sales to other segments	912	470	99	147	129	11	275	86	566	504	-1,980	-1,218	0	0
Total segment sales	28,660	25,953	13,085	14,916	12,570	9,991	2,874	2,738	566	504	-1,980	-1,218	55,774	52,884
Segment profit before interest and profit taxes (EBIT)	8,839	7,447	1,374	2,364	2,289	1,074	361	-38	-937	-833	0	2	11,926	10,016
Interest expenditures and revenues	-199	-192	-256	-172	-477	-488	-2	-24	218	283	0	-2	-716	-595
Income tax expense	-2,823	-2,372	-613	-815	-553	-310	-167	-55	0	-10	0	0	-4,156	-3,562
Profit before minority interests	5,817	4,883	505	1,377	1,259	276	192	-117	-719	-560	0	0	7,054	5,859

	Isotope Products		Radiation Therapy		Radiopharma		Environmental Services		Others		Total	
	01-06 2011	01-06 2010	01-06 2011	01-06 2010	01-06 2011	01-06 2010	01-06 2011	01-06 2010	01-06 2011	01-06 2010	01-06 2011	01-06 2010
	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR
Segmental assets	67,698	67,258	49,990	55,964	22,394	16,710	-*	-*	96,844	105,801	236,926	245,733
Elimination of inter-segmental shares, equity investments and receivables											-96,179	-97,834
Consolidated total assets											140,747	147,899
Segmental liabilities	-31,568	-33,163	-21,502	-25,776	-20,164	-19,754	-*	-*	-17,234	-25,409	-90,468	-104,102
Elimination of inter-segmental liabilities											25,826	27,931
Consolidated liabilities											-64,642	-76,171
Investments (without acquisitions)	1,876	589	1,334	994	540	675	161	101	1,698	4	5,609	2,363
Depreciation	-1,100	-1,155	-1,304	-1,445	-877	-959	-163	-223	-69	-89	-3,513	-3,871
Non-cash income/expenses	158	-18	-283	-424	-230	309	0	0	-433	131	-788	-2

\* In internal reporting, the asset and liability items of the Environmental Services segment are still shown in the Isotope Products segment. For this reason, the numbers are shown in the same way in the segment reporting.

Sales by regions	January - June 2011		January - June 2010	
	Million EUR	%	Million EUR	%
Europe	32.5	58	31.9	60
North America	16.5	30	15.4	30
Asia/Pacific	4.9	9	4.9	9
Others	1.9	3	0.7	1
Total	55.8	100	52.9	100

## Explanations for the interim financial statements

### 1. General information

These non-audited consolidated interim financial statements as of 30 June 2011 comprise the financial statements of Eckert & Ziegler Strahlen- und Medizintechnik AG and its subsidiaries (hereinafter also referred to as "Eckert & Ziegler AG").

### 2. Accounting and valuation methods

The consolidated financial statements (interim financial statements) of Eckert & Ziegler AG as of 30 June 2011 were prepared as the annual financial statements 2010 in line with the International Financial Reporting Standards (IFRS). All standards of the International Accounting Standards Board (IASB), London, which were to be applied in the EU on the financial statements key date, as well as the applicable interpretations of the International Financial Interpretations Committee (IFRIC) or of the Standing Interpretations Committee (SIC) were taken into consideration. The accounting and valuation methods explained in the notes to the annual financial statements 2010 were applied unchanged. For the preparation of the consolidated financial statements in line with the IFRS it is necessary that estimates and assumptions were made which have implications on the amount and disclosure of the accounted assets and debts, income and expenses. The actual values can deviate from the estimates. Essential assumptions and estimates are made for the useful lives, the income of the fixed assets which can be achieved, the ability to realise receivables and the accounting and valuation of provisions. This interim report contains all necessary information and adjustments, which are necessary for a picture of the net assets, financial position and results of operations of Eckert & Ziegler AG for the interim report which correspond with the actual circumstances. The results of the current fiscal year during the year do not necessarily allow conclusions to be drawn about the development of future results.

### 3. Group of consolidated companies

Included in the consolidated financial statements of Eckert & Ziegler AG are all companies with which Eckert & Ziegler AG indirectly or directly has the possibility to determine the financial and business policies (control concept).

#### *Company acquisitions and sales*

With regard to the company acquisitions and sales we refer to the explanations under Section 4.

### 4. Limited comparability of the consolidated financial statements with the previous year

The take-over offer for the shares of IBt S.A. which are not in the possession of Eckert & Ziegler AG, ended in March 2010, following which Eckert & Ziegler increased its participation share in the shares of IBt, which are entitled to a dividend, to 72%. In March 2010 the Eckert & Ziegler Group increased the shareholdings in Eckert & Ziegler EUROPET Berlin GmbH from 70% to 100%. In March 2010 the Eckert & Ziegler Group increased the shareholding in Eckert & Ziegler f-con Europe GmbH from 74% to 77%. As of the end of 2010 the shares in the company sonoTECH Gesellschaft für sonographische Technologie mbH were acquired. Compared with the first six months of 2010 this had essential implications on the net assets and results of operations of the Group through which the comparability of the group report with the previous year is impaired.

## 5. Currency conversion

The conversion of the financial statements of the companies outside of the European Monetary Union is carried out according to the concept of the functional currency. The following exchange rates were used for the currency conversion:

Country	Currency	Key date rate on June 30, 2011	Key date rate on Dec. 31, 2010	Average rate Jan. 1 - Jun. 30, 2011	Average rate Jan. 1 - Jun. 30, 2010
USA	USD	1.4390	1.3362	1.4067	1.3367
Czech Republic	CZK	24.3488	25.0610	24.2907	25.7743
Great Britain	GBP	0.8793	0.8565	0.8536	0.8674
Sweden	SEK	9.2177	8.9655	8.9403	9.8077

## 6. Stocks of own shares

As of 30 June 2011 4,818 own shares were held by Eckert & Ziegler AG. In calculable terms this corresponds with a share of 0.1% of the capital stock of the company.

## 7. Essential business with associated persons

With regard to the essential business with associated persons we refer to the publications in the consolidated annual financial statements as of 31 December 2010.

## 8. Addendum report

The radiopharmaceutical device division of Bioscan, Inc., which is based in Washington, D.C., was taken over as of 1 July 2011. It concerns on the one hand analytical instruments, which are used for the quality assurance of radioactive pharmaceutical products, on the other hand radiopharmaceutical synthesis devices. They are used in nuclear medicine worldwide with the production of short-lived contrast agents.

## 9. Information according to § 37y WpHG [Securities Trading Act] in conjunction with § 37w Par. 2 No. 3 WpHG

According to our best knowledge and belief we assure that pursuant to the applied principles of proper group interim reporting the consolidated interim financial statements give a true picture of the net assets, financial position and results of operations of the Group which corresponds with the actual circumstances, that the consolidated interim

management report presents the development of business


including the business results and the position of the Group to the extent that a picture is given which corresponds with the actual circumstances and that the essential opportunities and risks of the expected development of the Group in the remaining period of the fiscal year are described.

Berlin, 2 August 2011

Dr. Andreas Eckert  
Chairman of the Executive Board



Dr. Edgar Löffler  
Member of the Executive Board



Dr. André Heß  
Member of the Executive Board





## Financial Calendar

**13.09.2011**

9<sup>th</sup> German Healthcare Conference in Zurich

**02.11.2011**

Quarterly report III/2011

**23.11.2011**

German Equity Forum in Frankfurt

**30.03.2012**

Annual report 2011

**30.03.2012**

Balance press conference in Berlin

**May 2012**

Entry und General Standard Conference in Frankfurt

**03.05.2012**

Quarterly report I/2012

**24.05.2012**

Annual General Meeting

**14.08.2012**

Quarterly report II/2012

**06.11.2012**

Quarterly report III/2012

**November 2012**

German Equity Forum in Frankfurt

## Imprint

**Publisher**

Eckert & Ziegler AG

**Photographies**

Eckert & Ziegler AG

**Layout**

Salzkommunikation Berlin GmbH

## Contact

Eckert & Ziegler

Strahlen- und Medizintechnik AG

Karolin Riehle

Investor Relations

Robert-Rössle-Straße 10

13125 Berlin

[www.ezag.de](http://www.ezag.de)

Telephone +49 (0) 30 94 10 84 - 0

Telefax +49 (0) 30 94 10 84 - 112

E-Mail [info@ezag.de](mailto:info@ezag.de)

ISIN

DE0005659700

WKN

565970